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Plasma biomarkers are useful tools in the diagnosis and prognosis of heart failure (HF). In the 
last decade, numerous studies have aimed to identify novel HF biomarkers that would 
provide superior and/or additional diagnostic, prognostic, or stratification utility. Although 
numerous biomarkers have been identified, their implementation in clinical practice has so 
far remained largely unsuccessful. Whereas cardiac-specific biomarkers, including natriuretic 
peptides (ANP and BNP) and high sensitivity troponins (hsTn), are widely used in clinical 
practice, other biomarkers have not yet proven their utility. Galectin-3 (Gal-3) and soluble 
suppression of tumorigenicity 2 (sST2) are the only novel HF biomarkers that are included in 
the ACC/AHA HF guidelines, but their clinical utility still needs to be demonstrated. In this 
review, we will describe natriuretic peptides, hsTn, and novel HF biomarkers, including Gal-3, 
sST2, human epididymis protein 4 (HE4), insulin-like growth factor-binding protein 7 (IGFBP-
7), heart fatty acid-binding protein (H-FABP), soluble CD146 (sCD146), interleukin-6 (IL-6), 
growth differentiation factor 15 (GDF-15), procalcitonin (PCT), adrenomedullin (ADM), 
microRNAs (miRNAs), and metabolites like 5-oxoproline. We will discuss the biology of these 
HF biomarkers and conclude that most of them are markers of general pathological 
processes like fibrosis, cell death, and inflammation, and are not cardiac- or HF-specific. 
These characteristics explain to a large degree why it has been difficult to relate these 
biomarkers to a single disease. We propose that, in addition to clinical investigations, it will 
be pivotal to perform comprehensive preclinical biomarker investigations in animal models 
of HF in order to fully reveal the potential of these novel HF biomarkers. 
  




HEART FAILURE: A COMPLEX SYNDROME  
 
Heart failure (HF) is a complex syndrome that is characterized by reduced cardiac function 
and results in insufficient cardiac output to meet peripheral tissue metabolic demands1,2. It 
is prevalent in Western society, with more than 8% of the population aged 75 and older 
being diagnosed with HF1,3,4. Reduced cardiac output leads to the accumulation of fluid in 
lungs and other tissues, resulting in breathlessness, peripheral edema, and fatigue1. Thus, HF 
is not limited to cardiac dysfunction but also affects extra-cardiac organs and tissues. Due to 
different etiologies and underlying pathophysiological processes, HF is a heterogeneous 
disease, and plasma biomarkers could potentially contribute to the improvement of patient 
stratification and to guide therapy. In clinical association studies, many potential HF 
biomarkers have been identified and investigated for their diagnostic and prognostic values. 
Despite these efforts, limited progress has been made in introducing these novel biomarkers 
into daily clinical practice. Because HF can affect multiple organs, and these novel 
biomarkers are not exclusively expressed in the heart, it is difficult to draw conclusions from 
their plasma levels and to directly associate the levels with specific indices of cardiac 
remodeling and function. This issue needs to be clarified, and most likely it will require 
preclinical investigations in animal models of HF in addition to clinical studies. Numerous 
excellent reviews that discuss HF biomarkers have been published5-8, and this review is not 
meant to provide a complete overview of novel HF markers. Instead, we will briefly describe 
some novel (and established) HF biomarkers, and discuss them particularly in light of their 
(non-) cardiac nature and potential involvement in other diseases and conditions. We will 
outline challenges and pitfalls that we face and discuss why research should focus not only 
on clinical studies but also on preclinical studies using animal models. 
 
 
HEART FAILURE PATHOLOGY  
 
HF is the end-stage syndrome of most cardiovascular diseases, including myocardial 
infarction, hypertension, aortic stenosis, valve insufficiencies, and arrhythmias1,3,9. These 
diseases increase cardiac stress; to cope with this stress and to maintain cardiac function, 
morphological, structural, and functional alterations occur in the heart, a process termed 
cardiac remodeling10. Excessive extracellular matrix production (fibrosis) by fibroblasts and 
myofibroblasts, cardiomyocyte growth (hypertrophy), and infiltration of immune cells and 
elevated inflammation are the main processes that underlie cardiac remodeling11-14. Initially, 
these processes are beneficial and can be considered compensatory mechanisms, but with 
sustained cardiac stress, remodeling mechanisms eventually become pathological and 
reduce cardiac function10-14. Ongoing cardiac fibrosis results in stiffening of the cardiac 
muscular wall, which affects cardiac relaxation and contraction, may limit oxygen and 
nutrient diffusion and can disturb cardiac electrophysiology and induce rhythm 




alterations in Ca2+ handling, changes in excitation contraction coupling, sarcomere 
dysfunction, increased oxidative stress, and metabolic and energetic remodeling11-14. A 
vicious cycle is set up in which further deterioration of cardiac function stimulates further 
remodeling, which eventually may result in decompensated HF11,15.  
 
Different etiologies of HF result in different types of remodeling. For instance, myocardial 
infarction activates inflammatory pathways, stimulates replacement fibrosis and may drive 
eccentric hypertrophy, resulting in HF with reduced ejection fraction (HFrEF). Hypertension, 
on the other hand, may drive concentric hypertrophy and interstitial fibrosis, resulting in HF 
with preserved ejection fraction (HFpEF). Today HFpEF, which is often the result of 
hypertension, obesity, and aging, is becoming more prevalent16. A systemic proinflammatory 
state that causes coronary microvascular endothelial inflammation has been proposed as 
one of the main mechanisms that drives HFpEF development9. Coronary microvascular 
endothelial inflammation is believed to disturb the nitric oxide balance, protein kinase G 
(PKG) activity in adjacent cardiomyocytes may drive sarcomeric alterations, and, together 
with enhanced interstitial fibrosis, they promote diastolic dysfunction9. For HFrEF, 
therape tic options that incl de -blockers, angiotensin-converting-enzyme (ACE) inhibitors, 
and angiotensin receptor blockers (ARBs), which can slow down disease progression, are 
available; however, none of the current therapies have been shown to be successful in 
clinical trials with HFpEF. Together, this exemplifies that HF is not a single syndrome but a 
complex disorder, and we urgently need methods to distinguish the different HF modalities 
and underlying processes. 
 
In addition to the clinical investigation, echocardiography is an important tool to diagnose 
HF, and it can be used to distinguish certain types of HF and to monitor disease 
progression1,17. However, it does not provide insight in the underlying molecular and cellular 
processes. Plasma biomarkers have the potential to provide information about specific 
processes (e.g. interstitial/replacement fibrosis, endothelial dysfunction, and pathological 
hypertrophy) that drive cardiac dysfunction and the transition from compensated to 
decompensated HF in the individual HF patient; they may also add prognostic value and help 
in guiding therapy. 
 
 
ESTABLISHED HEART FAILURE BIOMARKERS 
 
Cardiac strain markers 
Several biomarkers have been included in the guidelines for HF treatment of the European 
Society of Cardiology (ESC) and American Heart Association (AHA)1,2. The scientific evidence 
for the use of natriuretic peptide levels is overwhelming and their use in the clinic is widely 
established18. The two most important variants, atrial-type natriuretic peptide (ANP) and B-
type natriuretic peptide (BNP), are mainly produced and secreted by the atria and ventricles, 




respectively18. Cardiac wall stress, generating mechanical strain in cardiomyocytes, enhances 
the production and secretion of these peptides19-21. ANP and BNP are synthesized as proANP 
and proBNP precursor proteins; upon secretion into the circulation, the N-terminal inactive 
domains (NT-proANP and NT-proBNP) are cleaved off, releasing the active ANP and BNP 
hormones22,23. ANP and BNP reduce peripheral vascular resistance and blood pressure by 
inducing a shift in fluid from the intravascular to the extravascular compartment, by 
promoting natriuresis, and by reducing the sympathetic tonus in peripheral vessels18,24. ANP 
and BNP are removed from the circulation by receptor-mediated internalization and 
metabolism and via proteolytic degradation by neprilysin (also termed neutral 
endopeptidase). Due to faster clearance of ANP by both pathways, the circulating half-life of 
ANP is only 3 min as compared to min for BNP  Beca se of its er  short half-life and its 
instability in plasma, ANP is not an attractive biomarker; thus either BNP or NT-proBNP (half-
life 60 min) are currently being used as biomarkers23,25. The stable mid-region of NT-
proANP, MR-proANP, is also mentioned in the ESC guidelines for diagnostic and prognostic 
purposes, particularly in acute HF1,26  
 
Plasma levels of natriuretic peptides are widely used in the diagnosis of patients who are 
suspected to have HF and are valuable in the evaluation of patients with both HFrEF and 
HFpEF1,27. Normal levels of natriuretic peptides largely exclude the presence of HF, and 
therefore levels are particularly useful to rule out HF, especially in the acute setting1,27-30. 
 
The levels of natriuretic peptides can be influenced by other syndromes and diseases, and 
kidney dysfunction is an important factor that may elevate natriuretic peptide levels31. In 
addition, obesity may be associated with lower natriuretic peptide concentrations and this 
may modestly reduce the diagnostic sensitivity in morbidly obese patients32. Importantly, 
with the positive results of clinical HF trials with entresto (LCZ-696)33,34, the introduction of 
this drug in daily clinical HF practice will make the interpretation of BNP levels in such 
treated patients more difficult. Entresto is made up of the angiotensin-receptor blocker 
(ARB) valsartan, and the neprilysin inhibitor prodrug sacubitril; the latter inhibits 
degradation of natriuretic peptides, thereby enhancing their beneficial effect during cardiac 
stress35. The concept that the lower the BNP levels in chronic HF patients, the better the 
prognosis during treatment monitoring will no longer hold true in these patients. Because 
NT-proBNP and MR-proANP are not subject to breakdown by neprilysin, these biomarkers 
can still be used for patient monitoring in this setting36. 
 
Cardiac injury markers 
Troponin I and T are another pair of proteins that are mentioned in the HF guidelines1,2. 
Troponins are released upon myocardial damage and elevated plasma levels of troponin 
point to acute coronary syndrome or pulmonary embolism as the cause of acute 
decompensation1,37. Like natriuretic peptides, the advantage of troponins is the cardiac 




not detected by the cardiac specific isoform assays38,39. With the development of high 
sensitivity cardiac troponin (hsTn) tests, elevated levels of cardiac troponin can be measured 
in the absence of acute myocardial damage, in particular in patients with stable chronic HF37. 
It has been suggested that troponins are also released during chronic low-grade cardiac 
ischemia, necrosis, apoptosis, and autophagy1,37. Therefore, hsTn can be elevated because of 
ongoing myocardial damage, which is present in patients with non-acute chronic HF, in the 
absence of a clear episode of myocardial ischemia1,37. The example of troponin shows that, 
although a marker can be tissue specific, in this case, cardiac specific, it is not necessarily 
disease specific (e.g. elevated in both acute myocardial ischemia due to myocardial 
infarction and chronic low grade myocardial damage in HF). Because dead cardiac myocytes 
are not renewed but are replaced by fibrosis11, it is tempting to suggest that cardiac 




Figure 1. Novel heart failure biomarkers are not cardiac specific. A schematic depiction of the contribution of 
the heart and other organs and tissues to circulating plasma levels of several protein/peptide heart failure (HF) 
biomarkers. Only a selection of biomarkers is cardiac specific and many (novel) HF biomarkers are also 
produced in other organs and tissues. Within the boxes, the names of the biomarkers and associated processes 
are shown. Abbreviations are explained in the text. 
Natriuretic peptides 
Cardiac strain 
Gal-3 / sST2 / HE4 
Fibrosis 











HsTn / H-FABP 
Cardiomyocyte injury 
Replacement fibrosis 
Metabolic profile / IGFBP-7 /  
5-oxoprolinase 




THE IMPASSE OF NOVEL HF BIOMARKERS 
 
Extracellular matrix turnover and remodeling markers 
Both natriuretic peptides and troponins show that different biomarkers provide different 
types of information. Therefore, a multi-marker approach has been suggested to combine 
the information provided by established and novel HF biomarkers to improve the current 
management and evaluation of HF patients. For this purpose, besides natriuretic peptides 
and troponins, the biomarkers, galectin-3 (Gal-3), and soluble suppression of tumorigenicity 
2 (sST2), were included in the American College of Cardiology (ACC)/AHA HF guidelines as 
markers of myocardial fibrosis, with a class IIb recommendation, to be considered for 
additional risk stratification of HF patients1,2. Gal-3 and sST2 and their relation to HF have 
been extensively investigated and reviewed6,7,40-42. The inclusion of these novel biomarkers 
in official guidelines supports their possible additive value, but despite numerous years of 
intense investigations, the potential of these biomarkers remains vague. 
 
Fibrosis marker Gal-3 
Galectin-3 (Gal-3) is a marker of organ fibrosis, including cardiac fibrosis7,43. Plasma levels are 
increased in patients with HF and can have additional prognostic value to NT-proBNP 
levels7,44. Many clinical association studies have shown that plasma levels of Gal-3 are 
associated with cardiac function and LV-filling pressures45,46. Moreover, studies in animal 
models of HF revealed that Gal-3 was involved in cardiac remodeling, and both genetic 
disruption and pharmacological inhibition of Gal-3 resulted in reduced cardiac remodeling, 
including myocardial fibrosis43,47-52. However, because HF is a multi-organ syndrome, other 
organs could also contribute to increased Gal-3 levels in HF. Gal-3 is expressed in multiple 
tissues and in different types of cells, including macrophages, eosinophils, neutrophils, and 
mast cells47,53. Gal-3 is also involved in renal fibrosis, as shown by several animal studies51,54, 
and plasma levels of Gal-3 are increased in several other diseases, including chronic 
obstructive pulmonary disease (COPD), and several types of cancer55-57. Therefore, it is likely 
that the observed increases in plasma levels of Gal-3 in HF are associated with increased 
cardiac Gal-3 production, but also with production in other organs and/or tissues. In line 
with this, Gal-3 is associated with HF comorbidities, including obesity58. Unfortunately, the 
HF clinical association studies and animal studies that have been performed do not provide 
full clarity on this matter. In some clinical studies, Gal-3 plasma levels were not directly 
related to specific cardiac parameters of HF, including echocardiographic parameters59. 
Moreover, a study in which endomyocardial biopsies were taken from dilated and 
inflammatory cardiomyopathy patients revealed that Gal-3 levels in these biopsies did not 
reflect plasma Gal-3 levels60. Finally, in HF patients with elevated Gal-3 plasma levels prior to 
heart transplantation, the levels did not decline post-transplantation, which indicated that 
other non-cardiac sources were predominantly responsible for elevated Gal-3 plasma levels 
in these patients61. Altogether, Gal-3 is not a cardiac-specific marker and it is unclear which 




HF. The use of Gal-3 as a biomarker for stratification of HF patients and as a marker of 
cardiac remodeling should therefore be interpreted in view of this possible multi-organ 
contribution. 
 
Fibrosis marker sST2 
Some of the issues discussed above also apply to sST2. Several clinical studies have shown 
that sST2 plasma levels are increased in patients with both acute and chronic HF and are 
predictive for HF outcome62,63. In both humans and mice, sST2 plasma levels are temporarily 
increased post-myocardial infarction, indicating that it could also act as a marker for 
myocardial injury64. ST2 has four isoforms, including sST2, ST2L, ST2V, and ST2LV; ST2L is the 
transmembrane isoform, and sST2 lacks transmembrane properties41. ST2L can interact with 
interleukin-33 (IL-33), and the ST2/IL33 interaction is involved in several diseases, including 
cardiovascular disease41,42. Triggered by cardiac strain or myocardial injury, cardiomyocytes 
and cardiac fibroblasts produce IL-33, which, by binding to ST2L, exerts cardioprotective 
effects by reducing cardiac hypertrophy and myocardial fibrosis41,42. sST2 is also produced by 
cardiomyocytes and cardiac fibroblasts, but it is associated with adverse cardiac remodeling 
via its competitive binding to IL-33, thereby limiting the protective effects of the ST2L/IL33 
interaction41,42,65. Thus a relationship exists between sST2 and cardiac dysfunction41,66. A 
recent st d  sho ed that sST  plasma le els normali ed ithin months post-implantation 
of a left ventricular assist device (LVAD) in end-stage HF patients67; this indicates that 
unloading the heart by LVAD placement lessens fibrosis. Because these are end-stage HF 
patients, many of whom will have multi-organ involvement, this finding may not be limited 
to the heart. In the ACC/AHA HF guidelines, sST2 has been included as a biomarker for 
myocardial fibrosis for further stratification of HF patients1,2. Like Gal-3, increased sST2 
plasma levels are also present in other diseases, including gastric cancer, breast cancer, 
nephropathy and liver disease68-71. Thus, although sST2 is able to promote cardiac 
remodeling locally, plasma levels of sST2 may be influenced by production in other organs in 
HF patients; hence circulating levels do not necessarily mirror cardiac production and 
remodeling. 
 
Fibrosis marker HE4 
The marker human epididymis protein 4 (HE4) is a recently discovered novel HF biomarker. 
HE4 is also known as the whey acidic protein four-disulfide core domain 2 (WFDC2 or WAP-
4C). Though the exact function of HE4 is yet unknown, a role for HE4 in fibrosis formation 
has been suggested because it shows similarities to extracellular proteinase inhibitors72,73. In 
a mouse model of renal disease, reduced fibrosis was observed in mice treated with HE4-
neutralizing antibodies74. In patients with both acute and chronic HF, HE4 levels were 
correlated with HF severity and could predict outcome in a multivariable model75,76. In both 
studies, HE4 levels in HF were correlated with Gal-3 and, therefore, probably with organ 
fibrosis. HE4, however, is not cardiac specific; its expression was first identified in the 
epididymis and later in many other tissues and organs72,77,78. Moreover, HE4 plasma levels 




are associated with several types of cancer77-79, including ovarian cancer80, and with chronic 
kidney disease (CKD) severity81. The association of HE4 levels with kidney function has also 
been replicated in cohorts comprised of acute and chronic HF patients75,76. It has been 
suggested that the elevated levels of HE4 in CKD patients may complicate its use in 
monitoring patients with epithelial ovarian cancer82, and the same is probably true in the HF 
setting. These multi-disease effects on HE4 plasma levels will mean that HE4 will not be 
useful for HF diagnosis, but, as part of a multi-biomarker model, it may have potential in the 
stratification of HF patients. HE4 has been included in such a model as an instrument to 
identify populations with a distinct therapy response. Patients with acute HF were 
investigated for response to treatment with the selective A1 adenosine receptor antagonist, 
rolofylline; in this study, the authors assessed tools to distinguish responders from non-
responders to therapy83. A multi-marker model, including HE4 plasma levels, tumor necrosis 
factor alpha receptor 1 (TNF-R  sST  and total cholesterol, appeared to be superior to 
clinical characteristics, including age, sex, and cardiac function, to differentiate non-
responders from responders. This study showed that multi-marker tools provide 
opportunities to improve clinical testing of novel drugs83. Moreover, this study is an example 




Metabolic marker IGFBP-7 
Insulin-like growth factor-binding protein 7 (IGFBP-7) can bind to insulin-like growth factor 1 
(IGF-1) and, by regulating the activity of the growth hormone/insulin-like growth factor-1 
(GH/IGF-1) system, it influences growth in various tissues. Its affinity for IGF-1 is relatively 
low compared to other IGFBPs84,85. It has, however, strong affinity for insulin, thereby 
reducing the binding of insulin to its receptor86. Interestingly, IGFBP-7 was investigated in an 
HF mouse model in which IGFBP-7 expression and plasma levels were increased in relation 
to cardiac hypertrophy, which showed a link between IGFBP-7 and HF development87. IGFBP-
7 levels were also elevated in serum of patients with both HFrEF and HFpEF88-90, and levels in 
these patients were also associated with prognosis88,89. As a biomarker, IGFBP-7 may be 
interesting especially for the HFpEF population90. First, IGFBP-7 has been associated with 
diastolic dysfunction, an important characteristic of HFpEF patients88-90. Second, IGFBP-7 
levels were associated with insulin resistance and metabolic syndrome risk91, which were 
associated with HFpEF development by causing chronic low-grade inflammation9. It has been 
suggested that, in a multi-marker approach, IGFBP-7 levels can be used to link abnormalities 
in cardiac function and morphology to disturbances in the metabolic status of patients90. 
Further investigations will be needed to establish this association with HFpEF. Urinary IGFBP-
7 levels are, together with tissue inhibitor of metalloproteinase 2 (TIMP-2), predictive for 
acute kidney injury in decompensated HF and post-coronary artery bypass surgery92-95. Thus, 
in addition to being a plasma biomarker, levels in other body fluids such as urine can provide 




also been associated with several other diseases, amongst them endometriosis, soft tissue 
sarcoma, and COPD96-98. 
 
Cardiac injury markers 
Cell death marker H-FABP 
Heart fatty acid-binding protein (H-FABP), which is produced predominantly in the heart, 
shows similarities to troponins as a marker. In cardiomyocytes, H-FABP is involved in cardiac 
metabolism through supplying mitochondria with long-chain fatty acids99. H-FABP is released 
upon ischemic myocardial damage and has been shown to be a myocardial injury marker in 
mice and in humans, especially in the early hours after myocardial infarction100-103. 
Interestingly, the prognostic capacity of H-FABP appears to be more accurate than hsTn 
levels; moreover, this also applies to patients with suspected acute coronary syndrome but 
with negative troponin levels99,104. Also, non-acute HF patients show ongoing myocardial 
damage and therefore, like hsTn, H-FABP is increased in chronic HF patients and will be a 
potential biomarker of myocardial damage105,106. It has been suggested that H-FABP is 
involved in a vicious cycle of deterioration in HF patients because extracellular H-FABP 
affects cardiac contraction by reducing intracellular Ca2+, which leads to more damage and 
therefore more extracellular H-FABP99. Indeed, increased H-FABP levels were observed in HF 
patients with ongoing myocardial damage, and these levels were prognostic for HF 
outcome105,106. Importantly, myocyte H-FABP levels are also influenced by exercise, plasma 
lipid levels, and PPAR-alpha agonists; hence, its intracellular levels reflect metabolic 
capacity107. In accordance with this, H-FABP  mice showed a reduced tolerance to physical 
activity and were rapidly exhausted by exercise108. In cardiac tissue, reduced fatty acid 
uptake was observed in these H-FABP  mice109. Although speculative, this suggests that the 
H-FABP/troponin plasma ratio could provide information about cardiomyocyte metabolic 




Inflammation marker IL-6 
Inflammation is an important process in HF, and substances related to inflammation, such as 
interleukin-6 (IL-6), could serve as HF biomarkers5,110. In the acute phase after myocardial 
infarction, IL-6 elevation is beneficial because it induces anti-apoptotic mechanisms in 
cardiomyocytes, and it is believed to limit infarct size110. However, IL-6 can also alter Ca2+ 
handling, and long-term IL-6 signaling is associated with depressed cardiomyocyte function, 
myocardial hypertrophy, and decreased contractility110,111. Limiting the long-term effects of 
IL-6 on the failing heart by blockade of the IL-6 receptor could therefore result in improved 
cardiac function, and the IL-6 receptor has been identified as an HF treatment target112. In an 
ischemia/reperfusion mouse model of HF, IL-6 receptor blockade resulted in neither reduced 
cardiac remodeling nor smaller infarct size; however, treatment was started during the acute 
phase, which could explain why no effects were observed113. Also, in humans, inhibition of 




IL-6 has been tested, but it was not able to improve coronary flow reserve in patients post-
myocardial infarction114. Nevertheless, because IL-6 has been shown to be involved in HF 
development, and because levels of this inflammatory marker are increased in HF and are 
able to predict outcome in various types of HF5,115-119, it could serve as a HF biomarker. The 
use of IL-6 in a multi-biomarker model has been suggested120, but circulating IL-6 levels are 
also affected by factors like stress, physical exercise, gender and age119. Moreover, 
circulating levels are also increased in non-HF patients; for example, elevated IL-6 plasma 
levels were predictive for post-operative complications in patients post-abdominal 
surgery121, and IL-6 levels were associated with outcome in acute stroke patients122. Thus, in 
HF, IL-6 could be a marker of inflammation in a multi-marker model, but this should be 
complemented by other markers to provide specificity and exclude other causes of elevated 
IL-6 levels. 
 
Inflammation marker GDF-15 
Growth differentiation factor 15 (GDF-15) is another inflammatory protein associated with 
HF. GDF-15 is a member of the transforming growth factor-beta superfamily123. Several 
studies have shown the involvement of GDF-15 in cardiac remodeling. In mouse 
cardiomyocytes cultured in vitro, GDF-15 expression and secretion were readily upregulated 
by ischemia/reperfusion stress, which was suggestive of autocrine/paracrine functions124. 
Mice lacking GDF-15 were more prone to ischemia/reperfusion damage, which indicated 
that GDF-15 could have cardioprotective effects (in contrast to other markers like Gal-3 and 
sST2)124. In particular, GDF-15 deficient mice showed increased recruitment of 
polymorphonuclear leukocytes to the infarct zone and had a higher chance to develop 
myocardial rupture125. GDF-15 also appears to be involved in myocardial hypertrophy, most 
likely through SMAD protein activation126. In patient cohorts, it was shown that circulating 
levels of GDF-15 were independent risk predictors for cardiovascular outcome127-129. 
Circulating levels are also associated with other diseases, for example, pulmonary 
embolism130, pulmonary arterial hypertension131, pneumonia, renal disease, and sepsis132. 
Plasma levels of GDF-15 cannot be directly associated with myocardial inflammation, but in a 
multi-marker model GDF-15, could improve risk prediction as a marker of general 
inflammation133. 
 
Inflammation marker PCT 
Procalcitonin (PCT) is an inflammatory marker that has been associated with HF and that is 
under clinical evaluation134. PCT, the prohormone of calcitonin, is secreted by different types 
of cells from numerous organs in response to proinflammatory stimulation. PCT levels are 
strongly elevated in bacterial infections, and it is an early marker for systemic inflammation, 
infection and sepsis; potentially it could be used to monitor patients and guide antibiotic 
therapy135. The half-life of PCT is abo t h  and the molec le is stable both in vivo and in 
vitro136. PCT was originally postulated to be a proxy for unrecognized infection in acute HF135. 




ESC-HF guidelines for the potential assessment of acute HF patients with suspected 
coexisting infection, particularly for the differential diagnosis of pneumonia and to guide 
antibiotic therapy137. Mollar et al.138 showed that PCT concentrations were also raised in 
patients admitted with acute HF with no evidence of infection and that it was associated 
with renal dysfunction and surrogates of venous congestion and inflammation. PCT has been 
shown to have prognostic value in acute HF patients, but whether this relates to 
concomitant infection rather than systemic inflammation requires further investigation134. 
Currently, the IMPACT-EU study (clinicaltrials.gov; NCT02392689), a large, multicenter, 
randomized controlled trial, is underway to compare PCT-guided patient management with 
standard management in emergency department patients with acute dyspnea and/or acute 
HF134. This study should confirm whether PCT-guided antibiotic therapy will improve patient 
outcome by early identification of acute HF patients with elevated PCT. 
 
Inflammation marker ADM 
Another member of the calcitonin gene-related peptide (CGRP) superfamily and potential HF 
biomarker is adrenomedullin (ADM)139. ADM is a 52-amino acid multifunctional peptide that 
exhibits vasodilatory potential and increases renal blood flow, natriuresis, and diuresis. Also, 
anti-inflammatory, anti-apoptotic, and proliferative properties have been linked to ADM, 
and it therefore appears to exhibit protective functions under diverse pathological 
conditions139. ADM is produced as a precursor protein called preproadrenomedullin in 
numerous tissues including adrenal glands, endothelium, vascular smooth muscles, renal 
parenchyma, and cardiomyocytes. This protein undergoes complex processing, first 
generating pro-ADM, which subsequently is cleaved into multiple peptides including mid-
regional proADM (MR-proADM) and ADM; the latter can exist in both a bioactive amidated 
form (bio-ADM) and a glycated inactive form140. Whether MR-proADM has biological activity 
is unclear, but because it is more stable than ADM, it is the preferred biomarker. Like PCT, 
MR-proADM is strongly elevated in sepsis and could be used as a prognostic marker and to 
guide the diagnosis and treatment of sepsis140. MR-proADM lacks specificity for the diagnosis 
of HF, but the BACH study demonstrated that MR-proADM had superior accuracy for 
predicting 90-day mortality compared with BNP in acute HF141. Recently, a sandwich 
immunoassay has been developed to measure bio-ADM in plasma. Like MR-proADM, bio-
ADM levels in acute HF patients were predictive for 30-day outcomes in these emergency 
department patients142. MR-proADM was also predictive for cardiovascular events in the 
general population143. Adrenomedullin is a substrate of neprilysin and hence its levels may 
be affected by treatment with neprilysin inhibitors; it has been suggested that the positive 
effects of neprilysin inhibition by sacubitril may be due in part to the inhibition of 
adrenomedullin and other bioactive peptides144. Despite many studies, there is no evidence 









Endothelial dysfunction marker CD146 
Cardiovascular diseases, including HF, are also characterized by endothelial damage145,146. 
Therefore, increased levels of a marker of endothelial cell damage could be a marker of 
disease severity. Moreover, such a biomarker could provide additional information about 
endothelial status. Different etiologies of endothelial injury are thought to result in the 
expression of different endothelial markers146. A novel marker of endothelial damage is 
soluble CD146 (sCD146; CD146, cluster of differentiation 146), which is a part of the junction 
between endothelial cells and which is responsible for maintaining tissue architecture147. 
Mechanical disruption of endothelial junctions probably results in shedding of the long 
CD146 isoform (CD146-L) present on endothelial cells, which results in sCD146 that can be 
found in the circulation146,148. sCD146 promotes angiogenesis, but also seems to be a marker 
of endothelial damage, atherosclerosis, and plaque instability149-152. In patients with acutely 
decompensated HF, circulating sCD146 levels were increased and could aid in diagnosing 
acute HF in patients who were difficult to stratify based on NT-proBNP levels only (e.g. in 
patients with NT-proBNP levels that were not high enough to include, but also not low 
enough to exclude, HF)153. In animal models of cardiac pressure overload, LV CD146 gene 
expression was increased and correlated with lung weight and therefore with lung 
congestion153. Also, in patients with pulmonary edema, the severity of the disease on chest 
radiography was associated with plasma levels of sCD146154. Interestingly, in a human model 
of peripheral venous congestion applied to one of the upper extremities of patients with 
chronic HF, sCD146 plasma levels increased whilst NT-proBNP remained stable155. It appears 
that circulating sCD146 levels can be related to peripheral vascular stretch, and moreover, 
that it is a marker of systemic congestion. Its plasma levels are also increased in liver 
cirrhosis, renal failure, atherosclerosis, and COPD152,156-159. Therefore, sCD146 seems to be a 
general marker of congestion and endothelial status in HF, but also in other diseases. 
 
 
LOOKING BEYOND CIRCULATING PROTEINS: MICRORNAs AND METABOLITES 
AS HF BIOMARKERS 
 
microRNAs 
In addition to using circulating proteins as HF biomarkers, recently several other circulating 
substances have been marked as potential novel HF biomarkers, including circulating 
microRNAs (miRNAs). The functions of miRNAs in HF, their role in the circulation and their 
potential as biomarkers are still elusive160. MiRNAs, which are post-transcriptional regulators 
of gene expression, were originally identified as regulators of embryonic development, 
including cardiac development160. Only later, a link between activation of the fetal gene 
program, miRNAs, and HF development was suggested160-162. For some solitary miRNAs, a 
role in pathological cardiac remodeling in animal models was found160,163-166. Also, in 




For example, myocardial and circulating miRNA-21 were both associated with the degree of 
myocardial fibrosis167. Several other studies showed associations between circulating 
miRNAs, including miR-20a, miR208b, and miR-34a, and processes of cardiac remodeling, 
making them potentially interesting biomarkers168,169. The miRNAs, miR-22-3p, miR-148b-3p, 
and miR-409-3p, were also associated with HF170,171. Interestingly, in human HF, decreased 
levels of a cluster of circulating miRNAs were associated with acute HF and were inversely 
correlated with biomarkers associated with worse clinical outcome172,173. Also, lower miRNA 
levels were associated with worsening of renal function174. When this set of circulating 
miRNAs identified in human samples was investigated in several rodent HF models, the 
observations in humans could not be replicated175. However, closer examination revealed 
that these miRNAs in humans were downregulated, particularly in acute HF, and not, or to a 
much lesser extent, in chronic HF. Moreover, a clear association with decreased circulating 
miRNAs and hemodilution, as a result of fluid overload, was observed in decompensated 
acute HF patients; this could at least partially explain the lowered circulating miRNA 
levels176. Also, comorbidities such as diabetes were present in the human HF cohort that 
were absent in the animal models. Therefore, in HF animal models, the cardiac phenotype 
was investigated without the influence of other HF comorbidities that may strongly affect 




Metabolic dysfunction is prevalent in HF and subsequent changes in metabolite profiles 
could potentially be used as HF biomarkers177. In HF, both myocardial and systemic changes 
in glucose oxidation, catabolism  -oxidation, and the urea cycle are responsible for 
observed alterations in metabolite levels177. Several studies have shown that a collection of 
metabolites can serve as diagnostic tools for HF178-181. However, changes in metabolite 
profiles seem not to be disease specific, because similar differences were observed in serum 
samples of patients with diseases such as non-Hodgkin lymphoma, congestive HF, and 
community-acquired pneumonia (CAP)182. In separate studies, the levels of the metabolite, 
trimethylamine N-oxide (TMAO) were shown to be associated with the outcome in both 
acute HF and CAP patients183,184. This is not surprising because systemic metabolic 
dysfunction is a general process that can be observed in other diseases. A recent study by 
van der Pol et al. identified the gene, OPLAH, which encodes 5-oxoprolinase (5-oxoprolinase, 
ATP-hydrolyzing), as a cardiac fetal-like gene that was suppressed in HF185. OPLAH functions 
to scavenge toxic 5-oxoproline, and diminished levels of OPLAH in animal HF models resulted 
in elevated levels of 5-oxoproline and associated oxidative stress in cardiac tissue. This could 
be reversed by cardiac-specific overexpression of OPLAH. Not only cardiac, but also plasma 
levels of 5-oxoproline were elevated in animals. Importantly, plasma 5-oxoproline levels 
were also elevated in acute HF patients, and patients with elevated levels showed a worse 
outcome. Although OPLAH is not exclusively expressed in the heart, cardiac levels are 
relatively high and hence 5-oxoproline levels in the plasma may be predominantly from 




cardiac expression. This makes 5-oxoproline a potentially interesting metabolite and 
biomarker that may be less affected by interference from non-cardiac sources as compared 
to other metabolites. 
 
 
THE PROMISE AND MAJOR HURDLE OF NEW BIOMARKERS 
 
As discussed above, plasma biomarkers have the potential to provide information about 
specific processes (e.g. cardiac strain, interstitial/replacement fibrosis, endothelial 
dysfunction, and pathological hypertrophic processes) that drive cardiac dysfunction in the 
individual HF patient; they may provide added prognostic value and could be used to 
improve and guide therapy. However, one major pitfall in this line of reasoning is that, 
except for cardiac strain and cardiomyocyte-specific cell death, these cellular and molecular 
processes are general processes and hence hallmarks of pathophysiological processes in 
other organs and tissues. Because HF is a multi-system disease affecting many tissues and 
organs throughout the body and because it is strongly associated with comorbidities, it is 
likely that these stress-related processes are also induced in non-cardiac tissues in these 
patients. Therefore, circulating levels of these plasma biomarkers in HF may demonstrate 
not only cardiac production but also production in other stressed tissues. Because these 
biomarkers monitor not only cardiac stress but also stress in other organs and tissues, it is 
not surprising that they have a strong prognostic value. Thus, although these novel 
biomarkers can provide insights in specific pathological processes, the lack of cardiac and/or 
HF specificity, as depicted in Figure 1 and Table 1, appears to hamper their clinical use. We 
postulate that this is the main reason why only the cardiac-specific HF biomarkers, especially 
natriuretic peptides and troponins, have found their way to the clinic, whereas non-cardiac 
specific markers are still under evaluation. This emphasizes that we must look at a different 
aspect of these novel biomarkers in order to exploit their potential. This will require more in-
depth research as discussed below. 
 
 
INCLUDE PRECLINICAL STUDIES IN ANIMALS IN THE INVESTIGATION OF NOVEL 
HF BIOMARKERS 
 
In a scientific statement from the AHA, criteria for the evaluation of novel biomarkers of 
cardiovascular risk have been proposed186. It is important to determine their clinical utility 
and, moreover, to determine whether the novel biomarker improves clinical outcomes in a 
cost-effective way. In a recent paper, Ahmad et al. stated that novel biomarkers should be 
approached in a more systematic manner with a focus on the clinical utility of the 






Table 1. Overview of selected (novel) heart failure (HF) biomarkers and associated conditions besides HF. 
Heart failure biomarker 
group 
Biomarkers Biomarker level also associated 
with 
References 
Biochemical strain Natriuretic peptides 
(i.e. BNP, NT-proBNP) 
Fluid overload 
Obesity (lowering of levels) 
Kidney dysfunction 
18,22-24,26,31,32,192 
Cardiomyocyte injury hsTn Myocardial infarction 37-39 
 H-FABP Myocardial infarction 99-103,105,106 
Extracellular matrix 
turnover and remodeling 





















 GDF-15 Pulmonary embolism 












 ADM Sepsis 










Soft tissue sarcoma 
COPD 
87,91-98 
Endothelial dysfunction CD146 Pulmonary edema 










Table legend for table 1. ADM=Adrenomedullin. BNP=Brain natriuretic peptide. COPD=Chronic obstructive 
pulmonary disease. Gal-3=Galectin-3. GDF-15=Growth differentiation factor 15. HE4=Human epididymis 
protein 4. H-FABP=Heart fatty acid-binding protein. hsTn=High sensitivity cardiac troponin. IGFBP-7=Insulin-like 
growth factor-binding protein 7. IL-6=Interleukin 6. MR-proANP=Mid-regional pro-atrial natriuretic peptide. NT-





Figure 2. Two pillars of HF biomarker research. Heart failure (HF) plasma biomarkers are currently 
predominantly investigated in clinical cohorts. Despite these investigations, progression in the clinical use of HF 
biomarkers is limited. Systematic improvements in clinical HF biomarker research have therefore been included 
to generate the required information186,187 We now propose an additional pillar of HF biomarker research, 
namely, the preclinical pillar, to provide additional information from studies in animals that should enhance our 
understanding, and together should pave the way to finally exploit these novel biomarkers. As in clinical 
studies, this will require systematic approaches and reports as indicated. 
 
 
We propose an additional pillar of HF biomarker research that has been largely neglected, 
namely preclinical investigations (Figure 2). As described in this review, a major issue is that 
most novel biomarkers are not cardiac and/or HF specific but are also associated with 
diseases affecting other organs and tissues. Currently, plasma levels of novel biomarkers are 
investigated in human clinical cohorts, providing at best associations, whilst plasma 
biomarkers are rarely investigated in HF animal models (preclinical studies), which could 
provide more causal insights. A simple PubMed search showed about ten times more 
published HF biomarker studies in patient cohorts as compared to preclinical HF biomarker 
studies. In contrast, investigations of cardiac remodeling processes such as cardiac 
hypertrophy and fibrosis are much more equally distributed between preclinical and clinical 
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provide more mechanistic insights required for proving causality (Figure 2). Preclinical animal 
studies could also provide us with accurate information regarding the exact tissue and cell 
sources that contribute to the HF biomarker plasma levels. Moreover, animal studies are 
well suited to investigate the effects of comorbidities on the plasma levels of biomarkers and 
to investigate time-related changes both in plasma and in other tissues (Figure 2). In clinical 
studies, we will at best be able to perform this in end-stage patients postmortem, but this 
will not provide information about the dynamics during HF development. Therefore, we 
suggest expanding translational animal experiments in which novel biomarkers can be 
studied at multiple levels. In line with clinical studies, these preclinical studies should be 
performed in a systematic manner and reported following guidelines such as the ARRIVE 
guidelines for animal studies188. It will also be crucial to invest in appropriate reagents to 
study biomarkers in animal models. So far, this has been a major limitation in animal studies, 
and even established HF biomarkers such as NT-proBNP and NT-proANP are seldom 
measured in mouse or rat studies because of the lack of good and affordable reagents (e.g. 
ELISA kits). Obviously, the small plasma volumes also make it challenging to measure these 
biomarkers in small animals. We believe that the current HF biomarker impasse can be 
broken by investing in preclinical studies to improve our understanding of these biomarkers, 





Established HF plasma biomarkers have proven their utility in the evaluation of HF patients, 
and novel HF biomarkers could further improve stratification of these patients. In the past 
decades, many novel HF biomarkers have been discovered and investigated in clinical trials. 
Despite these major efforts, only two novel biomarkers, Gal-3 and sST2, have been included 
in the ACC/AHA HF guidelines, but also their clinical value is still uncertain. Although these 
biomarkers can show specific molecular and cellular processes (e.g. fibrosis, hypertrophy), 
they lack cardiac and/or HF specificity. In Figure 1, a schematic depiction of the cardiac and 
non-cardiac specificity of HF plasma biomarkers is shown. This helps to explain why the 
investigated novel HF biomarkers have not yet been accepted into clinical use. Therefore, as 
depicted in Figure 2, we suggest including more in-depth preclinical investigations in animal 
models to gain insight into the relationship between plasma biomarker levels and the 
processes of cardiac remodeling, and into the potential contribution of other affected organs 
and tissues. Eventually, this should result in multi-biomarker models. To increase the 
predictive value of multi-marker panels requires a comprehensive evaluation of a broad set 
of biomarkers that represent the many pathophysiological pathways involved in HF, as 
described here. Serial evaluation of multi-marker panels is needed to maximize their 
prognostic utility189. These models could be used both to determine the right therapy regime 
and to guide therapy. The idea of a multi-biomarker model is not new, but to date, no real 
advances have been made in developing these types of models. This is most likely because of 




our lack of understanding of the contributions of other tissues to biomarker levels, and 
preclinical studies will therefore be indispensable. 
 
We suggest that analyzing non-cardiac specific HF biomarkers in a cardiac-specific way could 
be another way forward. Visualizing the local cardiac presence of these proteins and 
substances, for instance by using specific tracers in cardiac imaging, could provide direct 
information about the ongoing cardiac remodeling processes. Gal-3 could, for example, 
serve as a marker of myocardial fibrosis. This approach sounds futuristic, but for Gal-3, these 
types of tracers already exist190,191. Further research is needed to fully investigate this 
potential path to the utilization of non-cardiac specific biomarkers in a cardiac-specific 
manner. 
 
In conclusion, most novel HF biomarkers provide evidence of specific molecular and cellular 
processes, but in a non-cardiac specific fashion. Therefore, it is still unclear whether altered 
plasma biomarker levels represent solely cardiac production and can be directly associated 
with the degree of cardiac remodeling. Clinical association studies will not provide sufficient 
information to solve these issues, because cardiac samples are often not available and full 
body biomarker profiling will not be realistic or may be impossible. As shown in Figure 2, we 
therefore propose that comprehensive biomarker plasma and tissue profiling in preclinical 
HF models, in addition to biomarker plasma profiling in clinical cohorts, is necessary to fully 
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